Healthcare Industry News: IOERT
News Release - September 12, 2006
Stanford Hospital & Clinics Selects IntraOp Medical Corporation's Mobetron for Intraoperative Electron Radiation TherapyMobetron is the First Fully Portable, Self-Shielding Device That Directly Delivers Intraoperative Electron Radiation Therapy to Patients as They Undergo Surgery - Safely and Quickly
SUNNYVALE, Calif.--(HSMN NewsFeed)--Sept. 12, 2006--IntraOp Medical Corporation (OTCBB: IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced an order for a Mobetron® from Stanford Hospital & Clinics in Stanford, California. A fully portable, self-shielding electron-beam radiation unit, Mobetron directly delivers intraoperative electron radiation therapy ("IOERT") to patients as they undergo surgery in a highly safe and efficient manner. The system is planned to be installed in Spring 2007.
Stanford Hospital & Clinics is known worldwide for advanced patient care provided by its physicians and staff, particularly for the treatment of rare, complex disorders, including cancer. Stanford Comprehensive Cancer Center, leverages the world-class expertise of more than 240 researchers and clinicians on the most critical issues in cancer research and medicine today. The Center is keenly focused on providing patients with every clinical and technological advantage in the prevention and treatment of cancer.
Mobetron will replace Stanford Hospital's former intraoperative radiation therapy system, an Orthovoltage x-ray machine, and will be used to treat a wide variety of cancers, such as colorectal, gynecological, gastric, pancreatic, orthopedic, pediatric, breast and head and neck. With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel Mobetron between existing operating rooms without investing in costly renovations to accommodate traditional radiation therapy devices. Key patient benefits of this early and powerful start to radiation therapy include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects.
Donald A. Goer, President and CEO of IntraOp Medical Corporation said, "Stanford Hospital & Clinics is one of the leading centers for IORT treatment in the United States. We are delighted that such a well-respected and prestigious cancer care facility has selected our advanced medical technology solution to effectively treat a wide variety of cancers. This order is a testament to the growing strength of IORT worldwide and to the power, reliability and effectiveness of Mobetron. We look forward to working with Stanford Hospital & Clinics and with other IORT research centers to help make effective treatment a viable option for all cancer patients."
This is IntraOp's twenty-first order worldwide and the eighth in the United States. Other U.S. institutions using Mobetron include: University of California San Francisco, University of North Carolina, University Hospital Cleveland, Mayo Clinic Scottsdale, Ohio State University, Clarion Methodist Hospital Indianapolis and University of Louisville.
For more information on Stanford Hospital & Clinics, please visit: http://www.stanfordhospital.com
IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively - for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.
For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com
Source: IntraOp Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.